Drug intelligence / Profile preview

compound 3h

Development stage: Preclinical
Modality: Small Molecules
Administration: Intraperitoneal

Overview

Compound 3h is an experimental **small-molecule** 2-(4-(benzyloxy)-5-(hydroxyl) phenyl) benzothiazole derivative reported in a medicinal chemistry study as a multifunctional candidate for **Parkinson's disease**. It was described as a **potent, selective, competitive, and reversible monoamine oxidase B inhibitor**, with additional antioxidant activity, metal-chelating capacity, blood-brain barrier permeability, neuroprotective effects, and anti-neuroinflammatory activity in preclinical assays. Based on the provided source, it appears to be an early **preclinical research compound** from an academic discovery program rather than a named commercial or clinical-stage drug.

Other names: 2-(4-(benzyloxy)-5-(hydroxyl) phenyl) benzothiazole derivative 3h

Targets

PKM2 (Pyruvate kinase M2 isoform)

Beyond the preview

Go deeper on compound 3h.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on compound 3h.

Explore the full profile